(Q45865606)

17 December 2017

title

Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells (English)

1 reference

17 December 2017

1 reference

8

Curiel DT

1 reference

17 December 2017

Suzuki T

1

1 reference

17 December 2017

Anderegg B

2

1 reference

17 December 2017

Ohkawa T

3

1 reference

17 December 2017

Irie A

4

1 reference

17 December 2017

Engebraaten O

5

1 reference

17 December 2017

Halks-Miller M

6

1 reference

17 December 2017

Holm PS

7

1 reference

17 December 2017

Kashani-Sabet M

9

1 reference

17 December 2017

Scanlon KJ

10

1 reference

17 December 2017

publication date

1 February 2000

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

7

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

241-248

1 reference

17 December 2017

The neu oncogene encodes an epidermal growth factor receptor-related protein

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

c-erbB-2 oncogene as a prognostic marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Targeted tumor killing via an intracellular antibody against erbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Triplex formation inhibits HER-2/neu transcription in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

c‐erbB‐2 anti‐sense phosphorothioate oligodeoxynucleotides inhibit growth and serum‐induced cell spreading of p185c‐erbB‐2‐overexpressing ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Transcription of tal-1, a putative oncogene playing an important role in childhood T-ALL, can be shown in normal peripheral blood cells by a highly sensitive RT-PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

inferred from DOI database lookup

7 January 2021

based on heuristic

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301065

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3301065

1 reference

17 December 2017

Dimensions Publication ID

1040462250

0 references

1 reference

17 December 2017